Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2020 Elsevier Ltd Retinal degenerations account for the majority of untreatable causes of blindness. Advances in gene delivery vectors, CRISPR/Cas9-based gene editing systems, and electronic engineering have led to a wide range of strategies for correcting visual loss. Here, we provide an overview of retinal gene therapy, gene editing, optogenetics and retinal prostheses using examples from recent clinical trials and pre-clinical studies.

Original publication

DOI

10.1016/j.cophys.2020.03.003

Type

Journal article

Journal

Current Opinion in Physiology

Publication Date

01/08/2020

Volume

16

Pages

1 - 7